San Francisco, 19 March 2030: The Report C-reactive Protein Testing Market Size, Share & Trends Analysis Report By Assay Type (ELISA, CLIA), By Detection Range, By Disease Area, By End-use, By Region, And Segment Forecasts, 2023 - 2030

The global C-reactive protein testing market size is expected to reach USD 5.67 billion by 2030 and is projected to grow at a CAGR of 0.26% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of C-reactive protein (CRP) testing can be attributed to significant research activities aimed at exploring various applications of testing. These research efforts are further facilitated by the presence of both private and public agencies that provide funding to expedite research in this field. The market is anticipated to witness significant growth owing to advancements in nanotechnological tools. These advancements offer promising opportunities to develop portable bioanalytical assays that possess attributes, such as high specificity, sensitivity, rapid response time, and the ability to perform multiplexing for accurate disease diagnosis and monitoring at the point of care.

These advancements are expected to drive the demand for CRP testing during the forecast period. Furthermore, an increase in strategic deals and developments, as well as higher investments in research and development has fueled the growth. The COVID-19 pandemic has had a considerable impact on the market, as CRP is considered a crucial biomarker for assessing the severity of infection and inflammation. As a result, there is an increased demand for services and products. Leading companies, such as Abbott, provide supportive tools for CRP testing specifically for SARS-CoV-2 infection, further contributing to market growth. Moreover, key players increased focus on product launches and developments in point-of-care CRP tests, which is projected to further fuel the market's growth in the coming years.

For instance, in July 2022, Bloom Diagnostics introduced the Bloom Inflammation Test, a semi-automated testing kit designed for the quantification of CRP levels in the blood. This single-use kit aids in the detection of inflammation within the body. The growth of the marketplace is expected to be further stimulated by the establishment of testing facilities. In June 2021, Trivitron Healthcare unveiled a mobile laboratory for COVID-19 diagnostics, enabling testing services in various regions of India, including rural, urban, and remote areas. This indigenous laboratory offers a range of tests, including CLIA/Elisa tests for inflammatory markers, such as a CRP, IL-6, and D-Dimer, as well as rapid antigen tests, RT-PCR tests, CLIA/Elisa Antibodies Tests IgM and IgG, and others.

North America held the largest revenue share of 39.42% in 2022 and is expected to maintain its share during the forecast period due to the increasing prevalence of cardiovascular diseases, a steady stream of product launches, presence of established market players, technological advancements, and well-developed healthcare infrastructure. Asia Pacific is projected to grow at the fastest CAGR of 0.49% from 2023 to 2030. The COVID-19 pandemic originated in China. Being the potential biomarker for determining the severity of the infection, the demand for CRP testing is expected to increase shortly. Key players operating in the global industry are constantly focusing on product launches and geographical expansion to maintain their presence.

Request sample report of C-reactive Protein Testing Market@ https://www.grandviewresearch.com/industry-analysis/global-c-reactive-protein-testing-market/request/rs1

The market demand is anticipated to be driven by the growing prevalence of cardiovascular diseases, along with the increasing adoption of point-of-care devices. Furthermore, the growth of the market is expected to be propelled by increasing government initiatives for the implementation of point-of-care screening and the development of innovative techniques in C-reactive protein (CRP) testing. The growth of the market is being driven by several major factors such as the rising prevalence of chronic diseases such as inflammatory disorders, rheumatoid arthritis, and cardiovascular disease.

Moreover, there is an increasing incidence of endometriosis in women globally, which contributes to market growth. Furthermore, the growing demand for healthcare services also plays a significant role in driving the market. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC) in May 2023, approximately 1 in 20 adults aged 20 and older were affected by coronary artery disease (CAD) in 2021. In addition, in the U.S. alone, approximately 805,000 individuals experience a heart attack each year. Therefore, the increased prevalence of cardiovascular diseases has resulted in increased adoption of CRP testing to identify the associated risks, thereby driving the growth of the market.

Government agencies’ initiatives to increase awareness and adoption of point-of-care solutions, along with increased funding and investments for research entities engaged in relevant research activities, are significant factors driving market growth. Plasmonic Nanoparticles (PNPs) are recognized for their versatile optical properties, making them valuable tools for biosensing applications. For instance, Aidan provides user-friendly portable QuikRead go instrument and Quickread go CRP tests for quantitative measurements of CRP. Companies such as Aidian and Abbott provide products that are supportive diagnostic tools for managing COVID-19 infections. The COVID-19 pandemic had a positive impact on the market.

There was an increase in the demand for services and products, as CRP is a crucial biomarker for assessing the seriousness of infection and inflammation. Key market players have introduced supportive tools for CRP testing specifically for SARS-CoV-2 infection. For instance, in March 2020, Abbott launched ID NOW COVID-19, a rapid point-of-care (POC) CRP test capable of detecting COVID-19 within five minutes. In addition, several studies have been conducted on COVID-19 patients to assess CRP as a prognostic indicator. The significance of CRP testing in COVID-19 infection for patient stratification has resulted in an increased demand for CRP testing, thereby impacting market growth during the pandemic.

The market is anticipated to be driven by advancements in technology used for measuring CRP levels in patients. Significant investments are being made to develop new technologies that enhance the accuracy and adoption of CRP testing, further contributing to market growth. For instance, in November 2022, LumiraDx Healthcare Private Limited launched a highly sensitive CRP point-of-care antigen test in India. This test is designed to be utilized in various clinical settings and aims to reduce the unnecessary prescription of antibiotics, which thereby can contribute to the development of antimicrobial resistance.